Corvus Pharmaceuticals (CRVS) 10-Q 6 Aug 24 2024 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 06, 2024
Document And Entity Information
Document Quarterly Report	true
Document Transition Report	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2024
Entity Registrant Name	Corvus Pharmaceuticals, Inc.
Entity Tax Identification Number	46-4670809
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Securities Act File Number	001-37719
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	863 Mitten Road
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Burlingame
Entity Address, Postal Zip Code	94010
Entity Address, State or Province	CA
City Area Code	650
Local Phone Number	900-4520
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, Par Value $0.0001 per share
Security Exchange Name	NASDAQ
Trading Symbol	CRVS
Entity Common Stock, Shares Outstanding		62,551,281
Entity Central Index Key	0001626971
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 14,841	$ 12,620
Marketable securities	32,405	14,529
Accounts receivable - related party	35	26
Prepaid and other current assets	977	781
Total current assets	48,258	27,956
Property and equipment, net	192	236
Operating lease right-of-use asset	578	1,149
Investment in Angel Pharmaceuticals	15,404	16,123
Other assets	129	89
Total assets	64,561	45,553
Current liabilities:
Accounts payable	1,213	1,525
Operating lease liability	700	1,374
Accrued and other liabilities	4,304	3,970
Warrant liability	7,118
Total current liabilities	13,335	6,869
Total liabilities	13,335	6,869
Stockholders' equity:
Common stock: $0.0001 par value; 290,000,000 shares authorized at June 30, 2024 and December 31, 2023; 62,551,281 and 49,038,582 shares issued and outstanding at June 30, 2024 and December 31, 2023	6	5
Additional paid-in capital	397,255	374,363
Accumulated other comprehensive loss	(1,355)	(967)
Accumulated deficit	(344,680)	(334,717)
Total stockholders' equity	51,226	38,684
Total liabilities and stockholders' equity	$ 64,561	$ 45,553

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Preferred stock, shares authorized	10,000,000		10,000,000
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
Common stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Common stock, shares authorized	290,000,000		290,000,000
Common stock, shares issued	62,551,281	49,038,582
Common stock, shares outstanding	62,551,281	49,038,582

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses:
Research and development	$ 4,114	$ 3,968	$ 8,189	$ 8,562
General and administrative	1,821	1,654	3,999	3,634
Total operating expenses	5,935	5,622	12,188	12,196
Loss from operations	(5,935)	(5,622)	(12,188)	(12,196)
Interest income and other expense, net	434	403	750	779
Change in fair value of warrant liability	1,816		1,816
Sublease income - related party				56
Loss before equity method investment	(3,685)	(5,219)	(9,622)	(11,361)
Loss from equity method investment	(577)	(1,284)	(341)	(3,015)
Net loss	$ (4,262)	$ (6,503)	$ (9,963)	$ (14,376)
Net loss per share, basic	$ (0.07)	$ (0.14)	$ (0.18)	$ (0.31)
Net loss per share, diluted	$ (0.07)	$ (0.14)	$ (0.18)	$ (0.31)
Shares used to compute net loss per share, basic	59,710,265	47,497,414	54,374,423	47,029,396
Shares used to compute net loss per share, diluted	59,710,265	47,497,414	54,374,423	47,029,396
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	$ 5	$ (1)	$ (10)	$ 40
Cumulative foreign currency translation adjustment	(85)	(933)	(378)	(845)
Comprehensive loss	$ (4,342)	$ (7,437)	$ (10,351)	$ (15,181)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 5	$ 364,361	$ (563)	$ (307,688)	$ 56,115
Balance (in shares) at Dec. 31, 2022	46,553,511
Common stock issued on exercise of stock options		4			4
Common stock issued on exercise of stock options (in shares)	15,000
Stock-based compensation expense		492			492
Unrealized gain (loss) on marketable securities			41		41
Foreign currency translation adjustment			88		88
Net Income (Loss)				(7,873)	(7,873)
Balance at Mar. 31, 2023	$ 5	364,857	(434)	(315,561)	48,867
Balance (in shares) at Mar. 31, 2023	46,568,511
Balance at Dec. 31, 2022	$ 5	364,361	(563)	(307,688)	56,115
Balance (in shares) at Dec. 31, 2022	46,553,511
Foreign currency translation adjustment					(845)
Net Income (Loss)					(14,376)
Balance at Jun. 30, 2023	$ 5	372,910	(1,368)	(322,064)	49,483
Balance (in shares) at Jun. 30, 2023	48,898,362
Balance at Mar. 31, 2023	$ 5	364,857	(434)	(315,561)	48,867
Balance (in shares) at Mar. 31, 2023	46,568,511
Issuance of common stock in connection with at-the-market offering, net		7,516			7,516
Issuance of common stock in connection with at-the-market offering, net (in shares)	2,329,851
Stock-based compensation expense		537			537
Unrealized gain (loss) on marketable securities			(1)		(1)
Foreign currency translation adjustment			(933)		(933)
Net Income (Loss)				(6,503)	(6,503)
Balance at Jun. 30, 2023	$ 5	372,910	(1,368)	(322,064)	49,483
Balance (in shares) at Jun. 30, 2023	48,898,362
Balance at Dec. 31, 2023	$ 5	374,363	(967)	(334,717)	38,684
Balance (in shares) at Dec. 31, 2023	49,038,582
Stock-based compensation expense		689			689
Unrealized gain (loss) on marketable securities			(15)		(15)
Foreign currency translation adjustment			(293)		(293)
Net Income (Loss)				(5,701)	(5,701)
Balance at Mar. 31, 2024	$ 5	375,052	(1,275)	(340,418)	33,364
Balance (in shares) at Mar. 31, 2024	49,038,582
Balance at Dec. 31, 2023	$ 5	374,363	(967)	(334,717)	38,684
Balance (in shares) at Dec. 31, 2023	49,038,582
Foreign currency translation adjustment					(378)
Net Income (Loss)					(9,963)
Balance at Jun. 30, 2024	$ 6	397,255	(1,355)	(344,680)	51,226
Balance (in shares) at Jun. 30, 2024	62,551,281
Balance at Mar. 31, 2024	$ 5	375,052	(1,275)	(340,418)	33,364
Balance (in shares) at Mar. 31, 2024	49,038,582
Common stock issued with registered direct offering, net	$ 1	16,404			16,405
Common stock issued with registered direct offering, net (in shares)	13,512,699
Pre-funded warrants issued in connection with registered direct offering, net		5,031			5,031
Stock-based compensation expense		768			768
Unrealized gain (loss) on marketable securities			5		5
Foreign currency translation adjustment			(85)		(85)
Net Income (Loss)				(4,262)	(4,262)
Balance at Jun. 30, 2024	$ 6	$ 397,255	$ (1,355)	$ (344,680)	$ 51,226
Balance (in shares) at Jun. 30, 2024	62,551,281

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss	$ (9,963)	$ (14,376)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	44	93
Accretion related to marketable securities	(375)	(522)
Stock-based compensation	1,457	1,029
Change in fair value of warrant liability	(1,816)
Loss from equity method investment	341	3,015
Changes in operating assets and liabilities:
Accounts receivable - related party	(9)	588
Prepaid and other current assets	(196)	(120)
Operating lease right-of-use asset	571	526
Other assets	(40)
Accounts payable	(312)	122
Accrued and other liabilities	334	(3,087)
Operating lease liability	(674)	(602)
Net cash used in operating activities	(10,638)	(13,334)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of marketable securities	(30,922)	(33,808)
Maturities of marketable securities	13,411	34,155
Purchases of property and equipment		(34)
Net cash (used in) provided by investing activities	(17,511)	313
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Proceeds from issuance of common stock, net (includes $1,794 in aggregate gross proceeds from related parties for the six months ended June 30, 2024)	16,405
Proceeds from issuance of pre-funded warrants, net (includes $1,769 in aggregate gross proceeds from related parties for the six months ended June 30, 2024)	5,031
Proceeds from issuance of common warrants (includes $1,472 in aggregate gross proceeds from related parties for the six months ended June 30, 2024)	8,934
Proceeds from issuance of common stock in connection with at-the-market offering, net		7,516
Proceeds from exercise of common stock options		4
Net cash provided by financing activities	30,370	7,520
Net decrease in cash and cash equivalents	2,221	(5,501)
Cash and cash equivalents at beginning of the period	12,620	13,159
Cash and cash equivalents at end of the period	$ 14,841	$ 7,658

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Aggregate gross proceeds from related parties in connection with issuance of common stock	$ 1,794
Aggregate gross proceeds from related parties in connection with issuance of pre-funded warrants	1,769
Aggregate gross proceeds from related parties in connection with issuance of common warrants	$ 1,472

Organization

Organization	6 Months Ended
	Jun. 30, 2024
Organization
Organization	1. Organization ​ Corvus Pharmaceuticals, Inc. (“Corvus” or the “Company”) was incorporated in Delaware on January 27, 2014 and commenced operations in November 2014. Corvus is a clinical-stage biopharmaceutical company. The Company’s operations are located in Burlingame, California. ​ Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Corvus Biopharmaceuticals, Ltd. and Corvus Hong Kong Limited. All intercompany accounts and transactions have been eliminated from the condensed consolidated financial statements. ​ Initial Public Offering ​ ​ Follow-on Public Offerings ​ ​ ​ Registered Direct Offering ​ ​ Liquidity ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies ​ Basis of Presentation ​ The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company’s functional and reporting currency is the U.S. dollar, except for its investment in its equity method investee which is the Chinese renminbi (RMB). The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business. ​ Unaudited Interim Financial Information ​ The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for fair statement of the condensed consolidated financial statements presented. ​ The condensed consolidated balance sheet as of December 31, 2023 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2024. ​ Use of Estimates ​ The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates. ​ Investments in Equity Securities ​ ​ Concentrations of Credit Risk and Other Risks and Uncertainties ​ Substantially all of the Company’s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company’s marketable securities consist of investments in U.S. Treasury securities and U.S. government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. ​ The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. ​ Segments ​ Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, that of the development of and commercialization of precisely targeted oncology and immune-mediated therapies. ​ Warrants ​ ​ ​ Significant Accounting Policies ​ The Company’s significant accounting policies are described in Note 2 to its condensed consolidated financial statements for the year ended December 31, 2023, included in its Annual Report on Form 10-K. There have been no material changes to the Company’s significant accounting policies during the six months ended June 30, 2024 from those discussed in our Form 10-K. ​ Recent Accounting Pronouncements ​ In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU. ​ In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU’s amendments are effective for public business entities for annual periods beginning after December 15, 2024. Entities are permitted to early adopt the standard “for annual financial statements that have not yet been issued or made available for issuance.” As adoption is either prospectively or retrospectively, the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of this ASU but does not expect any material impacts upon adoption. ​

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2024
Net Loss per Share
Net Loss per Share	3. Net Loss per Share ​ The following table shows the calculation of net loss per share (in thousands, except share and per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ ​ 2024 2023 2024 2023 Numerator: ​ ​ ​ ​ ​ ​ ​ Net loss - basic and diluted ​ $ (4,262) ​ $ (6,503) ​ $ (9,963) ​ $ (14,376) ​ Denominator: ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used to compute basic and diluted net loss per share ​ 59,710,265 ​ 47,497,414 ​ 54,374,423 ​ 47,029,396 ​ Net loss per share, basic and diluted ​ $ (0.07) ​ $ (0.14) ​ $ (0.18) ​ $ (0.31) ​ ​ Weighted average common shares outstanding for the six months ended June 30, 2024 includes 4,144,085 shares of common stock issuable upon the conversion of pre-funded warrants described in Note 8. ​ The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ ​ 2024 2023 2024 2023 Common warrants ​ 17,089,436 — ​ 17,089,436 — ​ Outstanding options ​ 9,690,400 7,740,840 ​ 9,690,400 7,740,840 ​ ​

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Measurements
Fair Value Measurements	4. Fair Value Measurements ​ Financial assets and liabilities are measured and recorded at fair value. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: ​ ● Level 1—Quoted prices in active markets for identical assets or liabilities ​ ● Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly ​ ● Level 3—Unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability ​ There have been no transfers of assets and liabilities between levels of hierarchy. ​ The Company’s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs. ​ Financial Assets ​ The following tables present information as of June 30, 2024 and December 31, 2023 about the Company’s assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ Fair Value Measured Using ​ Total ​ (Level 1) (Level 2) (Level 3) Balance Assets ​ ​ ​ ​ Cash equivalents ​ $ 14,419 ​ $ — ​ $ — ​ $ 14,419 Marketable securities ​ 28,065 ​ 4,340 ​ — ​ 32,405 ​ ​ $ 42,484 ​ $ 4,340 ​ $ — ​ $ 46,824 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ Fair Value Measured Using ​ Total ​ (Level 1) (Level 2) (Level 3) Balance Assets ​ ​ ​ ​ Cash equivalents ​ $ 12,280 ​ $ — ​ $ — ​ $ 12,280 Marketable securities ​ ​ 10,356 ​ 4,173 ​ — ​ 14,529 ​ ​ $ 22,636 ​ $ 4,173 ​ $ — ​ $ 26,809 ​ As of June 30, 2024, all marketable securities had a maximum remaining maturity of less than two years. ​ As of June 30, 2024 and December 31, 2023, the fair value of available for sale marketable securities by type of security were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ ​ Gross Gross ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ Fair ​ ​ Cost ​ Gains ​ Losses ​ Value U.S. Treasury securities ​ $ 28,060 ​ $ 6 ​ $ (1) ​ $ 28,065 U.S. Government agency securities ​ ​ 4,340 ​ ​ — ​ ​ — ​ ​ 4,340 ​ ​ $ 32,400 ​ $ 6 ​ $ (1) ​ $ 32,405 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ ​ Gross Gross ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ Fair ​ ​ Cost ​ Gains ​ Losses ​ Value U.S. Treasury securities ​ $ 10,348 ​ $ 8 ​ $ — ​ $ 10,356 U.S. Government agency securities ​ ​ 4,166 ​ ​ 7 ​ ​ — ​ ​ 4,173 ​ ​ $ 14,514 ​ $ 15 ​ $ — ​ $ 14,529 ​ ​ ​ ​ Financial Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ Fair Value Measured Using ​ Total ​ (Level 1) (Level 2) (Level 3) Balance Warrant liability ​ $ — ​ $ — ​ $ 7,118 ​ $ 7,118 ​ ​ During the six months ended June 30, 2024, the changes in the Company’s warrant liability were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Warrant liability balance as of December 31, 2023 ​ $ — Issuance of warrants ​ ​ 8,934 Change in fair value ​ ​ (1,816) Warrant liability balance as of June 30, 2024 ​ $ 7,118 ​ The Company uses the Black-Scholes pricing model to determine the fair value of its warrant liabilities using Level 3 inputs. Inputs used to determine estimated fair value of the warrant liabilities include the fair value of the underlying stock at the valuation date, the term of the warrants, and the expected volatility of the underlying stock. The significant unobservable input used in the fair value measurement of the warrant liabilities is the estimated term of the warrants. ​ The key inputs into valuation models used to estimate the fair value of the warrant liabilities as of May 6, 2024, the issuance date, and as of June 30, 2024 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ May 6, ​ ​ ​ ​ ​ ​ 2024 ​ ​ June 30, ​ ​ (Date of ​ ​ 2024 ​ ​ Issuance) ​ Risk-free interest rate ​ 5.1 % ​ ​ 5.1 % Expected volatility ​ 104.2 % ​ ​ 104.4 % Expected term (in years) ​ 1.0 ​ ​ ​ 1.2 ​ Share price $ 1.82 ​ ​ $ 1.91 ​ ​

Equity Method Investment

Equity Method Investment	6 Months Ended
	Jun. 30, 2024
Equity Method Investment
Equity Method Investment	​ 5. Equity Method Investment Angel Pharmaceuticals Co. Ltd. (“Angel”) is a corporate venture in the People’s Republic of China designed to develop, manufacture, and commercialize soquelitinib, ciforadenant and mupadolimab compounds for distribution within the countries of China, Taiwan, Macao, and Hong Kong based on intellectual property licenses to be contributed to Angel by the Company. As of June 30, 2024 and December 31, 2023, the Company’s ownership interest in Angel was approximately 49.7%, excluding 7% of Angel’s equity reserved for issuance under the Angel Employee Stock Ownership Plan, and is accounted for as an equity method investment. The Company recognized its share of income/loss in Angel for the total amount of $0.6 million and $0.3 million as loss from equity method investment in the condensed consolidated statement of operations for the three and six months ended June 30, 2024, respectively. Summary Financial Information Summary financial information for Angel Pharmaceuticals is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of Balance Sheet Data June 30, 2024 ​ December 31, 2023 ​ (in thousands) Current assets ​ $ 16,205 ​ $ 17,628 Non-current assets ​ 1,192 ​ 1,427 Current liabilities ​ 1,028 ​ 1,725 Non-current liabilities ​ 531 ​ 648 Stockholders' equity ​ ​ 15,838 ​ ​ 16,682 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ Statement of Operations Data 2024 ​ 2023 ​ 2024 ​ 2023 ​ ​ (in thousands) ​ Revenue ​ $ — ​ $ — ​ $ — ​ $ — ​ Gross Profit ​ — ​ — ​ — ​ — ​ Net income (loss) ​ ​ (677) ​ ​ (1,620) ​ ​ (432) ​ ​ (3,549) ​ Share of loss from investments accounted for using the equity method ​ (577) ​ (1,284) ​ (341) ​ (3,015) ​ ​

License and Collaboration Agree

License and Collaboration Agreements	6 Months Ended
	Jun. 30, 2024
License and Collaboration Agreements
License and Collaboration Agreements	6. License and Collaboration Agreements ​ Scripps Licensing Agreement ​ In December 2014, the Company entered into a license agreement with The Scripps Research Institute (“Scripps”), pursuant to which it was granted a non-exclusive, world-wide license for all fields of use under Scripps’ rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma, from which we developed mupadolimab. Scripps also granted the Company the right to grant sublicenses in conjunction with other proprietary rights the Company holds, or to others collaborating with or performing services for the Company. Under this license agreement, Scripps has agreed not to grant any additional commercial licenses with respect to such materials, other than march-in rights granted to the U.S. government. ​ Upon execution of the agreement, the Company made a one-time cash payment to Scripps of $10,000 and is also obligated to pay a minimum annual fee to Scripps of $25,000. The first minimum annual fee payment is due on each anniversary of the effective date of the agreement and will be due on each subsequent anniversary of the effective date for the term of the agreement. The Company is also required to make performance-based cash payments upon successful completion of clinical and sales milestones. The aggregate potential milestone payments are $2.6 million. The Company is also required to pay royalties on net sales of licensed products (including mupadolimab) sold by it, its affiliates and its sublicensees at a rate in the low-single digits. In addition, should the Company sublicense the rights licensed under the agreement, it has agreed to pay a percentage of sublicense revenue received at specified rates that start at double digit percentages and decrease to single digit percentages based on the elapsed time from the effective date of the agreement and the time of entry into such sublicense. To date, no milestone payments have been made. ​ The Company’s license agreement with Scripps will terminate upon expiration of its obligation to pay royalties to Scripps under the license agreement. The Company’s license agreement with Scripps is terminable by the consent of the parties, at will by the Company upon providing 90 days written notice to Scripps, or by Scripps for certain material breaches, or if the Company undergoes a bankruptcy event. In addition, Scripps may terminate the license on a product-by-product basis, or the entire agreement, if the Company fails to meet specified diligence obligations related to the development and commercialization of licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably believes, based on reports the Company provides to Scripps, that the Company has not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure period. ​ Vernalis Licensing Agreement ​ In February 2015, the Company entered into a license agreement with Vernalis (R&D) Limited (“Vernalis”), which was subsequently amended as of November 5, 2015, and, pursuant to which the Company was granted an exclusive, worldwide license under certain patent rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor antagonists, including ciforadenant. Pursuant to this agreement, the Company made a one-time cash payment to Vernalis in the amount of $1.0 million, which was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The Company is also required to make cash milestone payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on the indications for which such licensed products are developed and upon achievement of certain sales milestones. In February 2017, the Company made a milestone payment of $3.0 million to Vernalis following the expansion of a cohort of patients with renal cell cancer treated with single agent ciforadenant in the Company’s Phase 1/1b clinical trial. During the six months ended June 30, 2024, no clinical or regulatory milestones were completed or paid to Vernalis and the aggregate potential milestone payments were approximately $220 million for all indications as of June 30, 2024. The Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing ciforadenant on a product by product and country by country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing ciforadenant range from the mid single digits up to the low double digits on a country by country net sales basis. The royalties on other licensed products that do not include ciforadenant also increase with the amount of net sales on a product-by-product and country by country basis and range from the low single digits up to the mid single digits on a country by country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above when worldwide net sales reach specified levels over an agreed upon time period. ​ The Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing ciforadenant on a product-by-product and country-by-country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing ciforadenant range from the mid-single digits up to the low-double digits on a country-by-country net sales basis. The royalties on other licensed products that do not include ciforadenant also increase with the amount of net sales on a product-by-product and country-by-country basis and range from the low-single digits up to the mid-single digits on a country-by-country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above when worldwide net sales reach specified levels over an agreed upon time period. ​ The agreement will expire on a product-by-product and country-by-country basis upon the expiration of the Company’s payment obligations to Vernalis in respect of a particular product and country. Both parties have the right to terminate the agreement for an uncured material breach by the other party. The Company may also terminate the agreement at its convenience by providing 90 days written notice, provided that the Company has not received notice of its own default under the agreement at the time the Company exercises such termination right. Vernalis may also terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event. ​ Monash License Agreement In April 2017, the Company entered into a license agreement with Monash University (Monash), pursuant to which the Company was granted an exclusive, sublicensable worldwide license under certain know-how, patent rights and other intellectual property rights controlled by Monash to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases. Upon execution of the agreement, the Company made a one time cash payment to Monash of $275,000 and reimbursed Monash for certain patent prosecution costs incurred prior to execution of the agreement. The Company recorded these payments as research and development expenses for the year ended December 31, 2017. The Company is also obligated to pay an annual license maintenance fee to Monash of $25,000 until a certain development milestone is met with respect to the licensed product, after which no further maintenance fee will be due. The Company is also required to make development and sales milestone payments to Monash with respect to the licensed products. During the six months ended June 30, 2024 and 2023, no development or sales milestones were completed or paid to Monash and the aggregate potential milestones were $45.1 million as of June 30, 2024. The Company is also required to pay to Monash tiered royalties on net sales of licensed products sold by it, its affiliates and its sublicensees at a rate ranging in the low single digits. In addition, should the Company sublicense its rights under the agreement, the Company has agreed to pay a percentage of sublicense revenue received at specified rates that are currently at low double digit percentages and decrease to single digit percentages based on the achievement of development milestones. The term of the Company’s agreement with Monash continues until the expiration of its obligation to pay royalties to Monash thereunder. The license agreement is terminable at will by the Company upon providing 30 days written notice to Monash, or by either party for material breaches by the other party. In addition, Monash may terminate the entire agreement or convert the license to a non-exclusive license if the Company has materially breached its obligation to use commercially reasonable efforts to develop and commercialize a licensed product, subject to a specified notice and cure mechanism.

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2024
Balance Sheet Components
Balance Sheet Components	7. Balance Sheet Components (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2024 2023 Prepaid and Other Current Assets ​ ​ ​ ​ ​ ​ ​ Interest receivable ​ $ 87 ​ $ 37 ​ Prepaid research and development manufacturing expenses ​ ​ 146 ​ ​ 149 ​ Prepaid facility expenses ​ ​ 196 ​ ​ 196 ​ Prepaid insurance ​ ​ 308 ​ ​ 179 ​ Other ​ 240 ​ 220 ​ ​ ​ $ 977 ​ $ 781 ​ Property and Equipment ​ ​ ​ ​ ​ ​ ​ Laboratory equipment ​ $ 2,537 ​ $ 2,678 ​ Computer equipment and purchased software ​ 171 ​ 171 ​ Leasehold improvements ​ 2,084 ​ 2,084 ​ ​ ​ 4,792 ​ 4,933 ​ Less: accumulated depreciation and amortization ​ (4,600) ​ (4,697) ​ ​ ​ $ 192 ​ $ 236 ​ Accrued and Other Liabilities ​ ​ ​ ​ ​ ​ ​ Accrued clinical trial expense ​ $ 2,591 ​ $ 2,302 ​ Accrued manufacturing expense ​ 478 ​ 675 ​ Personnel related ​ 683 ​ 684 ​ Accrued legal and accounting ​ ​ 322 ​ ​ 64 ​ Other ​ 230 ​ 245 ​ ​ ​ $ 4,304 ​ $ 3,970 ​ ​ During the three months ended June 30, 2024 and 2023, the Company recorded approximately $21,000 and $36,000 in depreciation expense, respectively, and during the six months ended June 30, 2024 and 2023, the Company recorded approximately $44,000 and $93,000 in depreciation expense, respectively.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2024
Warrants
Warrants	8. Warrants ​ ​ ​ 2025. In accordance with accounting guidance discussed in Note 2, the Company recorded $8.9 million to warrant liability upon issuance of the common warrants on May 6, 2024 and recorded a change in fair value of warrant liability of $1.8 million

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2024
Common Stock
Common Stock	9. Common Stock ​ As of June 30, 2024, the amended and restated certificate of incorporation authorizes the Company to issue 290 million shares of common stock and 10 million shares of preferred stock. ​ Each share of common stock is entitled to one vote. Common stockholders are entitled to dividends if and when declared by the board of directors. As of June 30, 2024, no dividends on common stock had been declared. ​ On March 28, 2023, the Company entered into an open market sale agreement (the “2023 Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, from time-to-time, with aggregate gross sales proceeds of up to $90.0 million, through an at-the-market equity offering program under which Jefferies will act as its sales agent. The issuance and sale of shares of common stock by the Company pursuant to the 2023 Sales Agreement are deemed an “at-the-market” offering under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services equal to 3.0% of the gross proceeds of any shares of common stock sold through Jefferies under the 2023 Sales Agreement. ​ On May 1, 2024, the Company amended the 2023 Sales Agreement to decrease the aggregate gross sales proceeds that may be sold pursuant to the 2023 Sales Agreement from $90.0 million to $8.2 million, which decreased the amount available for sale to $100,000. During the six months ended June 30, 2024, the Company did not sell any shares of common stock under its at-the-market offering program. As of June 30, 2024, $100,000 remained available for sale under the 2023 Sales Agreement. ​ The Company has reserved shares of common stock for issuance as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2024 2023 Pre-funded warrants 4,144,085 ​ — Outstanding common warrants ​ 17,089,436 ​ — ​ Shares available for future option grants ​ 5,132,693 ​ 3,617,943 ​ Outstanding options 9,690,400 ​ 9,244,150 Shares reserved for employee stock purchase plan 400,000 ​ 400,000 Total 36,456,614 ​ 13,262,093 ​

Stock Option Plans

Stock Option Plans	6 Months Ended
	Jun. 30, 2024
Stock Option Plans
Stock Option Plans	10. Stock Option Plans ​ In February 2014, the Company adopted the 2014 Equity Incentive Plan (the “2014 Plan”), which was subsequently amended in November 2014, July 2015 and September 2015, under which it granted incentive stock options (“ISOs”) or non-qualified stock options (“NSOs”). Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2014 Plan. In general, awards granted by the Company vest over four years and have a maximum exercise term of 10 years. The 2014 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company’s common stock as determined by the board of directors on the date of the grant. ​ In connection with the consummation of the IPO in March 2016, the 2016 Equity Incentive Award Plan (the “2016 Plan”), became effective. Under the 2016 Plan, incentive stock options, non-statutory stock options, stock purchase rights and other stock-based awards may be granted. Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2016 Plan. In general, awards granted by the Company vest over four years and have a maximum exercise term of 10 years. The 2016 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company’s common stock as determined by the board of directors on the date of the grant. In conjunction with adopting the 2016 Plan, the 2014 Plan was terminated and no further awards will be granted under the 2014 Plan. Options outstanding under the 2014 Plan as of the effective date of the 2016 Plan that are forfeited or lapse unexercised may be re-issued under the 2016 Plan, up to a maximum of 1,136,229 shares. ​ Activity under the Company’s stock option plans is set forth below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ ​ Weighted ‑ ​ ​ Shares ​ ​ ​ Average ​ ​ Available ​ Number of ​ Exercise ​ for Grant Options Price Balance at December 31, 2023 3,617,943 9,244,150 ​ $ 4.17 Additional shares authorized 1,961,000 — ​ — Options granted (525,000) 525,000 ​ 2.26 Options forfeited 78,750 (78,750) ​ 1.84 Balance at June 30, 2024 5,132,693 9,690,400 ​ $ 4.08 ​

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2024
Stock-Based Compensation
Stock-Based Compensation	11. Stock-Based Compensation ​ The Company’s results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ ​ 2024 2023 2024 2023 Research and development ​ $ 229 ​ $ 184 ​ $ 449 ​ $ 376 ​ General and administrative ​ 539 ​ 353 ​ 1,008 ​ 653 ​ Total ​ $ 768 ​ $ 537 ​ $ 1,457 ​ $ 1,029 ​ ​

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Taxes
Income Taxes	12. Income Taxes ​ During the six months ended June 30, 2024 and 2023, the Company recorded no income tax benefits for the net operating losses (NOLs) incurred due to the uncertainty of realizing a benefit from those items. The Company continues to maintain a full valuation allowance against its net deferred tax assets.

Facility Lease

Facility Lease	6 Months Ended
	Jun. 30, 2024
Facility Lease
Facility lease	13. Facility Lease ​ In January 2015, the Company signed an initial operating lease, effective February 1, 2015 for 8,138 square feet of office and laboratory space with a one year term. Between January 2015 and September 2021, the Company entered into a series of lease amendments to increase the amount of leased space to 27,280 square feet and extend the expiration of the lease to January 2025. The lease agreement includes annual rent escalations. Under the lease and subsequent amendments, the landlord provided approximately $1.9 million in free rent and lease incentives. The Company records rent expense on a straight-line basis over the effective term of the lease, including any free rent periods and incentives. As the interest rate implicit in lease arrangements is typically not readily available, in calculating the present value of the lease payments, the Company has utilized its incremental borrowing rate, which was determined based on the prevailing market rates for collateralized debt with maturity dates commensurate with the term of its lease. The Company’s facility lease is a net lease, as the non-lease components (i.e. common area maintenance) are paid separately from rent based on actual costs incurred. Therefore, the non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred. ​ As of June 30, 2024 and December 31, 2023, the right-of-use asset under operating lease was $0.6 million and $1.1 million, respectively. The elements of lease expense for the three and six months ended June 30, 2024 and 2023 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ Statements of operations and June 30, ​ June 30, ​ ​ comprehensive loss location ​ 2024 2023 2024 2023 Costs of operating lease ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ Research and development, ​ $ 306 ​ $ 306 ​ $ 615 ​ $ 612 Costs of non-lease components (previously common area maintenance) ​ Research and development, ​ ​ 115 ​ ​ 85 ​ ​ 242 ​ ​ 196 Total operating lease cost ​ ​ ​ $ 421 ​ $ 391 ​ $ 857 ​ $ 808 Other Information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows used for operating lease ​ ​ ​ $ 473 ​ $ 460 ​ $ 946 ​ $ 919 Remaining lease term ​ ​ ​ 0.6 years ​ 1.6 years ​ 0.6 years ​ 1.6 years Discount rate ​ ​ ​ 8.0% ​ 8.0% ​ 8.0% ​ 8.0% ​ ​ ​ ​ ​ ​ Year Ended December 31 (in thousands) ​ ​ 2024* ​ $ 717 Total lease payments ​ 717 Less: imputed interest ​ ​ (17) Total $ 700 * Remainder of the year ​ ​ ​ ​ ​ ​ Year Ended December 31 (in thousands) ​ ​ 2024 ​ $ 1,434 Total lease payments ​ 1,434 Less: imputed interest ​ ​ (60) Total $ 1,374 ​

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies
Commitments and Contingencies	14. Commitments and Contingencies ​ ​ Indemnifications ​ In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. There have been no claims to date and the Company has a directors and officers insurance policy that may enable it to recover a portion of any amounts paid for future claims. ​ Legal Proceedings ​

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Related Party Transactions
Related Party Transactions	15. Related Party Transactions ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Number of Number of ​ Aggregate ​ ​ ​ Shares of ​ Pre-Funded ​ Common ​ Purchase ​ Common Stock Warrants Warrants Price OrbiMed Advisors LLC (1) ​ ​ — ​ ​ 1,444,085 ​ ​ 1,397,684 ​ $ 2,499,856 Puissance Capital Management (2) ​ ​ 866,451 ​ ​ — ​ ​ 838,610 ​ ​ 1,500,000 Richard A. Miller, M.D. (3) ​ ​ 577,634 ​ ​ — ​ ​ 559,073 ​ ​ 1,000,000 William B. Jones, Ph.D. (4) ​ ​ 20,001 ​ ​ — ​ ​ 19,358 ​ ​ 34,624 (1) Peter Thompson, M.D., a member of our Board of Directors since November 2014, is a Private Equity Partner at OrbiMed Advisors, LLC. (2) Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a 49.7% ownership interest, is the founder of Puissance Capital Management. (3) Richard A. Miller, M.D. is the Company’s President, Chief Executive Officer and Chairman of the Board. (4) William B. Jones, Ph.D. is the Company’s Senior Vice President, Pharmaceutical Development. ​ party and internal personnel costs incurred by the Company are billed to Angel Pharmaceuticals in the period incurred and recorded as an offset to expenses. During the six months ended June 30, 2024 and 2023, the Company billed Angel for approximately $9,000 and $48,000, respectively, in third-party party costs. As of June 30, 2024 and December 31, 2023, the Company had approximately $35,000 and $26,000, respectively, in accounts receivable – related party due from Angel Pharmaceuticals. ​ ​ ​

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (4,262)	$ (5,701)	$ (6,503)	$ (7,873)	$ (9,963)	$ (14,376)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Summary of Significant Accounting Policies
Basis of Presentation	​ Basis of Presentation ​ The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company’s functional and reporting currency is the U.S. dollar, except for its investment in its equity method investee which is the Chinese renminbi (RMB). The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business.
Unaudited Interim Financial Information	​ Unaudited Interim Financial Information ​ The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for fair statement of the condensed consolidated financial statements presented. ​ The condensed consolidated balance sheet as of December 31, 2023 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2024. ​
Use of Estimates	Use of Estimates ​ The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.
Concentrations of Credit Risk and Other Risks and Uncertainties	​ Concentrations of Credit Risk and Other Risks and Uncertainties ​ Substantially all of the Company’s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company’s marketable securities consist of investments in U.S. Treasury securities and U.S. government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. ​ The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. ​
Segments	Segments ​ Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, that of the development of and commercialization of precisely targeted oncology and immune-mediated therapies.
Warrants	Warrants ​ ​
Significant Accounting Policies	Significant Accounting Policies ​ The Company’s significant accounting policies are described in Note 2 to its condensed consolidated financial statements for the year ended December 31, 2023, included in its Annual Report on Form 10-K. There have been no material changes to the Company’s significant accounting policies during the six months ended June 30, 2024 from those discussed in our Form 10-K. ​
Investments in Equity Securities	Investments in Equity Securities ​
Recent Accounting Pronouncements	Recent Accounting Pronouncements ​ In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU. ​ In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU’s amendments are effective for public business entities for annual periods beginning after December 15, 2024. Entities are permitted to early adopt the standard “for annual financial statements that have not yet been issued or made available for issuance.” As adoption is either prospectively or retrospectively, the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of this ASU but does not expect any material impacts upon adoption. ​

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Net Loss per Share
Schedule of net loss per share, basic and diluted	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ ​ 2024 2023 2024 2023 Numerator: ​ ​ ​ ​ ​ ​ ​ Net loss - basic and diluted ​ $ (4,262) ​ $ (6,503) ​ $ (9,963) ​ $ (14,376) ​ Denominator: ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used to compute basic and diluted net loss per share ​ 59,710,265 ​ 47,497,414 ​ 54,374,423 ​ 47,029,396 ​ Net loss per share, basic and diluted ​ $ (0.07) ​ $ (0.14) ​ $ (0.18) ​ $ (0.31) ​
Schedule of antidilutive securities excluded from calculation of diluted net loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ ​ 2024 2023 2024 2023 Common warrants ​ 17,089,436 — ​ 17,089,436 — ​ Outstanding options ​ 9,690,400 7,740,840 ​ 9,690,400 7,740,840 ​ ​

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Measurements
Schedule of fair value of assets measured at fair value on a recurring basis, by level of fair value hierarchy	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ Fair Value Measured Using ​ Total ​ (Level 1) (Level 2) (Level 3) Balance Assets ​ ​ ​ ​ Cash equivalents ​ $ 14,419 ​ $ — ​ $ — ​ $ 14,419 Marketable securities ​ 28,065 ​ 4,340 ​ — ​ 32,405 ​ ​ $ 42,484 ​ $ 4,340 ​ $ — ​ $ 46,824 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ Fair Value Measured Using ​ Total ​ (Level 1) (Level 2) (Level 3) Balance Assets ​ ​ ​ ​ Cash equivalents ​ $ 12,280 ​ $ — ​ $ — ​ $ 12,280 Marketable securities ​ ​ 10,356 ​ 4,173 ​ — ​ 14,529 ​ ​ $ 22,636 ​ $ 4,173 ​ $ — ​ $ 26,809 ​ As of June 30, 2024, all marketable securities had a maximum remaining maturity of less than two years.
Schedule of fair value of available for sale marketable securities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ ​ Gross Gross ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ Fair ​ ​ Cost ​ Gains ​ Losses ​ Value U.S. Treasury securities ​ $ 28,060 ​ $ 6 ​ $ (1) ​ $ 28,065 U.S. Government agency securities ​ ​ 4,340 ​ ​ — ​ ​ — ​ ​ 4,340 ​ ​ $ 32,400 ​ $ 6 ​ $ (1) ​ $ 32,405 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ ​ ​ Gross Gross ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ Fair ​ ​ Cost ​ Gains ​ Losses ​ Value U.S. Treasury securities ​ $ 10,348 ​ $ 8 ​ $ — ​ $ 10,356 U.S. Government agency securities ​ ​ 4,166 ​ ​ 7 ​ ​ — ​ ​ 4,173 ​ ​ $ 14,514 ​ $ 15 ​ $ — ​ $ 14,529
Schedule of fair value of liabilities measured at fair value on a recurring basis, by level of fair value hierarchy	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2024 ​ ​ Fair Value Measured Using ​ Total ​ (Level 1) (Level 2) (Level 3) Balance Warrant liability ​ $ — ​ $ — ​ $ 7,118 ​ $ 7,118 ​
Schedule of changes in warrant liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Warrant liability balance as of December 31, 2023 ​ $ — Issuance of warrants ​ ​ 8,934 Change in fair value ​ ​ (1,816) Warrant liability balance as of June 30, 2024 ​ $ 7,118
Schedule of inputs and valuation technique to estimate the fair value of warrant liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ May 6, ​ ​ ​ ​ ​ ​ 2024 ​ ​ June 30, ​ ​ (Date of ​ ​ 2024 ​ ​ Issuance) ​ Risk-free interest rate ​ 5.1 % ​ ​ 5.1 % Expected volatility ​ 104.2 % ​ ​ 104.4 % Expected term (in years) ​ 1.0 ​ ​ ​ 1.2 ​ Share price $ 1.82 ​ ​ $ 1.91 ​ ​

Equity Method Investment (Table

Equity Method Investment (Tables)	6 Months Ended
	Jun. 30, 2024
Equity Method Investment
Schedule of financial information of Angel Pharmaceuticals Co.	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of Balance Sheet Data June 30, 2024 ​ December 31, 2023 ​ (in thousands) Current assets ​ $ 16,205 ​ $ 17,628 Non-current assets ​ 1,192 ​ 1,427 Current liabilities ​ 1,028 ​ 1,725 Non-current liabilities ​ 531 ​ 648 Stockholders' equity ​ ​ 15,838 ​ ​ 16,682 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ Statement of Operations Data 2024 ​ 2023 ​ 2024 ​ 2023 ​ ​ (in thousands) ​ Revenue ​ $ — ​ $ — ​ $ — ​ $ — ​ Gross Profit ​ — ​ — ​ — ​ — ​ Net income (loss) ​ ​ (677) ​ ​ (1,620) ​ ​ (432) ​ ​ (3,549) ​ Share of loss from investments accounted for using the equity method ​ (577) ​ (1,284) ​ (341) ​ (3,015) ​ ​

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2024
Balance Sheet Components
Schedule of balance sheet components	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2024 2023 Prepaid and Other Current Assets ​ ​ ​ ​ ​ ​ ​ Interest receivable ​ $ 87 ​ $ 37 ​ Prepaid research and development manufacturing expenses ​ ​ 146 ​ ​ 149 ​ Prepaid facility expenses ​ ​ 196 ​ ​ 196 ​ Prepaid insurance ​ ​ 308 ​ ​ 179 ​ Other ​ 240 ​ 220 ​ ​ ​ $ 977 ​ $ 781 ​ Property and Equipment ​ ​ ​ ​ ​ ​ ​ Laboratory equipment ​ $ 2,537 ​ $ 2,678 ​ Computer equipment and purchased software ​ 171 ​ 171 ​ Leasehold improvements ​ 2,084 ​ 2,084 ​ ​ ​ 4,792 ​ 4,933 ​ Less: accumulated depreciation and amortization ​ (4,600) ​ (4,697) ​ ​ ​ $ 192 ​ $ 236 ​ Accrued and Other Liabilities ​ ​ ​ ​ ​ ​ ​ Accrued clinical trial expense ​ $ 2,591 ​ $ 2,302 ​ Accrued manufacturing expense ​ 478 ​ 675 ​ Personnel related ​ 683 ​ 684 ​ Accrued legal and accounting ​ ​ 322 ​ ​ 64 ​ Other ​ 230 ​ 245 ​ ​ ​ $ 4,304 ​ $ 3,970 ​

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2024
Common Stock
Schedule of shares of common stock reserved for issuance	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2024 2023 Pre-funded warrants 4,144,085 ​ — Outstanding common warrants ​ 17,089,436 ​ — ​ Shares available for future option grants ​ 5,132,693 ​ 3,617,943 ​ Outstanding options 9,690,400 ​ 9,244,150 Shares reserved for employee stock purchase plan 400,000 ​ 400,000 Total 36,456,614 ​ 13,262,093 ​

Stock Option Plans (Tables)

Stock Option Plans (Tables)	6 Months Ended
	Jun. 30, 2024
Stock Option Plans
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ ​ Weighted ‑ ​ ​ Shares ​ ​ ​ Average ​ ​ Available ​ Number of ​ Exercise ​ for Grant Options Price Balance at December 31, 2023 3,617,943 9,244,150 ​ $ 4.17 Additional shares authorized 1,961,000 — ​ — Options granted (525,000) 525,000 ​ 2.26 Options forfeited 78,750 (78,750) ​ 1.84 Balance at June 30, 2024 5,132,693 9,690,400 ​ $ 4.08 ​

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Stock-Based Compensation
Schedule of expenses relating to employee and non-employee stock-based awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ ​ 2024 2023 2024 2023 Research and development ​ $ 229 ​ $ 184 ​ $ 449 ​ $ 376 ​ General and administrative ​ 539 ​ 353 ​ 1,008 ​ 653 ​ Total ​ $ 768 ​ $ 537 ​ $ 1,457 ​ $ 1,029 ​ ​

Facility Lease (Tables)

Facility Lease (Tables)	6 Months Ended
	Jun. 30, 2024
Facility Lease
Schedule of components of lease expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ Statements of operations and June 30, ​ June 30, ​ ​ comprehensive loss location ​ 2024 2023 2024 2023 Costs of operating lease ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ Research and development, ​ $ 306 ​ $ 306 ​ $ 615 ​ $ 612 Costs of non-lease components (previously common area maintenance) ​ Research and development, ​ ​ 115 ​ ​ 85 ​ ​ 242 ​ ​ 196 Total operating lease cost ​ ​ ​ $ 421 ​ $ 391 ​ $ 857 ​ $ 808 Other Information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows used for operating lease ​ ​ ​ $ 473 ​ $ 460 ​ $ 946 ​ $ 919 Remaining lease term ​ ​ ​ 0.6 years ​ 1.6 years ​ 0.6 years ​ 1.6 years Discount rate ​ ​ ​ 8.0% ​ 8.0% ​ 8.0% ​ 8.0%
Schedule of Minimum rental commitments	​ ​ ​ ​ ​ Year Ended December 31 (in thousands) ​ ​ 2024* ​ $ 717 Total lease payments ​ 717 Less: imputed interest ​ ​ (17) Total $ 700 * Remainder of the year ​ ​ ​ ​ ​ Year Ended December 31 (in thousands) ​ ​ 2024 ​ $ 1,434 Total lease payments ​ 1,434 Less: imputed interest ​ ​ (60) Total $ 1,374 ​

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2024
Related Party Transactions
Schedule of common stock sold to related parties	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Number of Number of ​ Aggregate ​ ​ ​ Shares of ​ Pre-Funded ​ Common ​ Purchase ​ Common Stock Warrants Warrants Price OrbiMed Advisors LLC (1) ​ ​ — ​ ​ 1,444,085 ​ ​ 1,397,684 ​ $ 2,499,856 Puissance Capital Management (2) ​ ​ 866,451 ​ ​ — ​ ​ 838,610 ​ ​ 1,500,000 Richard A. Miller, M.D. (3) ​ ​ 577,634 ​ ​ — ​ ​ 559,073 ​ ​ 1,000,000 William B. Jones, Ph.D. (4) ​ ​ 20,001 ​ ​ — ​ ​ 19,358 ​ ​ 34,624 (1) Peter Thompson, M.D., a member of our Board of Directors since November 2014, is a Private Equity Partner at OrbiMed Advisors, LLC. (2) Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a 49.7% ownership interest, is the founder of Puissance Capital Management. (3) Richard A. Miller, M.D. is the Company’s President, Chief Executive Officer and Chairman of the Board. (4) William B. Jones, Ph.D. is the Company’s Senior Vice President, Pharmaceutical Development.

Organization - Public Offerings

Organization - Public Offerings (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended		3 Months Ended				6 Months Ended
	May 06, 2024	Apr. 26, 2016	Mar. 29, 2016	Feb. 28, 2021	Mar. 31, 2018	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Public Offerings
Proceeds from sale of stock										$ 16,405
Net cash used in operating activities										10,638	$ 13,334
Net loss						$ 4,262	$ 5,701	$ 6,503	$ 7,873	9,963	$ 14,376
Accumulated deficit						344,680				344,680		$ 334,717
Cash, cash equivalents and short-term marketable securities						$ 47,200				$ 47,200
Warrants issued to purchase common shares						8,934,000				8,934,000
Common stock, par value (in dollars per share)						$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001
Common Stock
Public Offerings
Common shares issued in transaction						13,512,699
Pre-Funded Warrants | Warrants
Public Offerings
Warrants issued to purchase common shares						4,144,085				4,144,085
Initial Public Offering
Public Offerings
Net proceeds from IPO		$ 70,600
Common shares issued in transaction			4,700,000
Offering price per share			$ 15
Over-allotment Option
Public Offerings
Common shares issued in transaction		502,618		1,212,231	1,058,823
Offering price per share		$ 15
Follow-on Public Offering
Public Offerings
Proceeds from sale of stock				$ 32,000	$ 64,900
Common shares issued in transaction				9,783,660	8,117,647
Offering price per share				$ 3.50	$ 8.50
Registered Direct Offering
Public Offerings
Proceeds from sale of stock	$ 30,600
Registered Direct Offering | Common Stock
Public Offerings
Common shares issued in transaction	13,512,699
Registered Direct Offering | Warrants
Public Offerings
Warrants issued to purchase common shares	13,078,509
Offering price per share	$ 1.7312
Registered Direct Offering | Common Warrants | Common Stock
Public Offerings
Exercise price of warrants	$ 3.50
Registered Direct Offering | Common Warrants | Warrants
Public Offerings
Warrants issued to purchase common shares	4,010,927
Offering price per share	$ 1.7311
Exercise price of warrants	$ 3.50
Registered Direct Offering | Pre-Funded Warrants | Warrants
Public Offerings
Warrants issued to purchase common shares	4,144,085
Offering price per share	$ 1.7311
Exercise price of pre-funded warrants in lieu of common share warrants	3.4999
Exercise price of warrants	$ 0.0001

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($) item segment	Dec. 31, 2023 USD ($)
Summary of Significant Accounting Policies
Accumulated deficit	$ (344,680)	$ (334,717)
Cash, cash equivalents and marketable securities	47,200
Accumulated other comprehensive income	$ (1,355)	$ (967)
Concentrations of Credit Risk and Other Risks and Uncertainties
Number of financial institutions used for cash and cash equivalent deposits | item	2
Segment Reporting [Abstract]
Number of operating segments | segment	1

Net Loss per Share - Net Loss p

Net Loss per Share - Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator:
Net loss - basic and diluted	$ (4,262)	$ (5,701)	$ (6,503)	$ (7,873)	$ (9,963)	$ (14,376)
Denominator:
Weighted average shares used to compute net loss per share, basic	59,710,265		47,497,414		54,374,423	47,029,396
Weighted average shares used to compute net loss per share, diluted	59,710,265		47,497,414		54,374,423	47,029,396
Net loss per share, basic	$ (0.07)		$ (0.14)		$ (0.18)	$ (0.31)
Net loss per share, diluted	$ (0.07)		$ (0.14)		$ (0.18)	$ (0.31)
Warrants included in weighted average common shares outstanding	8,934,000				8,934,000
Pre-Funded Warrants | Warrants
Denominator:
Warrants included in weighted average common shares outstanding	4,144,085				4,144,085

Net Loss per Share - Anti-Dilut

Net Loss per Share - Anti-Dilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Common Warrants
Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect
Anti dilutive securities were excluded from the calculation of diluted net loss per share	17,089,436		17,089,436
Outstanding options
Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect
Anti dilutive securities were excluded from the calculation of diluted net loss per share	9,690,400	7,740,840	9,690,400	7,740,840

Fair Value Measurements - Recur

Fair Value Measurements - Recurring (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Assets
Maximum remaining maturity of marketable securities	2 years
Fair Value, Recurring
Assets
Cash equivalents	$ 14,419	$ 12,280
Marketable securities	32,405	14,529
Total Assets	46,824	26,809
Fair Value, Recurring | Level 1 Inputs
Assets
Cash equivalents	14,419	12,280
Marketable securities	28,065	10,356
Total Assets	42,484	22,636
Fair Value, Recurring | Level 2 Inputs
Assets
Marketable securities	4,340	4,173
Total Assets	$ 4,340	$ 4,173

Fair Value Measurements - Avail

Fair Value Measurements - Available For Sale (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair value of available for sale marketable securities
Amortized Cost	$ 32,400	$ 14,514
Gross Unrealized Gains	6	15
Gross Unrealized Losses	(1)
Fair Value	32,405	14,529
US Treasury Securities
Fair value of available for sale marketable securities
Amortized Cost	28,060	10,348
Gross Unrealized Gains	6	8
Gross Unrealized Losses	(1)
Fair Value	28,065	10,356
US Government Agencies Securities
Fair value of available for sale marketable securities
Amortized Cost	4,340	4,166
Gross Unrealized Gains		7
Fair Value	$ 4,340	$ 4,173

Fair Value Measurements - Finan

Fair Value Measurements - Financial Liabilities (Details) - USD ($)	Jun. 30, 2024	May 06, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Warrant liability	$ 7,118,000	$ 8,900,000
Financial liabilities			$ 0
Fair Value, Recurring
Class of Warrant or Right [Line Items]
Warrant liability	7,118,000
Fair Value, Recurring | Level 3 Inputs
Class of Warrant or Right [Line Items]
Warrant liability	$ 7,118,000

Fair Value Measurements - Warra

Fair Value Measurements - Warrant Liability (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	May 06, 2024	Jun. 30, 2023
Class of Warrant or Right [Line Items]
Issuance of warrants	8,934	8,934
Change in fair value	$ (1,800)	$ (1,816)
Warrant liability balance as of June 30, 2024	$ 7,118	$ 7,118
Fair value measurement input, share price	$ 0.0001	$ 0.0001		$ 0.0001
Warrants | Risk-free Interest Rate
Class of Warrant or Right [Line Items]
Fair value measurement input, warrants	5.10%	5.10%	5.10%
Warrants | Expected Volatility
Class of Warrant or Right [Line Items]
Fair value measurement input, warrants	104.20%	104.20%	104.40%
Warrants | Expected Term (in years)
Class of Warrant or Right [Line Items]
Fair value measurement input, warrant term	1 year	1 year	1 year 2 months 12 days
Warrants | Share Price
Class of Warrant or Right [Line Items]
Fair value measurement input, share price	$ 1.82	$ 1.82	$ 1.91

Equity Method Investment (Detai

Equity Method Investment (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Equity Method Investments [Line Items]
Net Income (Loss)	$ (4,262)	$ (5,701)	$ (6,503)	$ (7,873)	$ (9,963)	$ (14,376)
Share of loss from investments accounted for using the equity method	$ (577)		$ (1,284)		$ (341)	$ (3,015)
Angel Pharmaceuticals
Schedule of Equity Method Investments [Line Items]
Ownership interest (as percent)	49.70%		49.70%		49.70%	49.70%
Equity reserved (as percent)					7%	7%
Income (loss) from equity method investment					$ (600)	$ 300
Net Income (Loss)	$ (677)		$ (1,620)		(432)	(3,549)
Share of loss from investments accounted for using the equity method	$ (577)		$ (1,284)		$ (341)	$ (3,015)

Equity Method Investment - Summ

Equity Method Investment - Summary Financial Information (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Current assets	$ 48,258		$ 27,956
Current liabilities	13,335		6,869
Stockholders' equity	51,226	$ 33,364	38,684	$ 49,483	$ 48,867	$ 56,115
Angel Pharmaceuticals
Schedule of Equity Method Investments [Line Items]
Current assets	16,205		17,628
Non-current assets	1,192		1,427
Current liabilities	1,028		1,725
Non-current liabilities	531		648
Stockholders' equity	$ 15,838		$ 16,682

License and Collaboration Agr_2

License and Collaboration Agreements (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Apr. 30, 2017	Feb. 28, 2017	Dec. 31, 2015	Nov. 05, 2015
Monash License
License and Collaboration Agreements
Period of written notice to terminate	30 days
Licensing Agreement | Scripps Research Institute
License and Collaboration Agreements
Minimum annual fee				$ 25,000
Aggregate potential milestone payments	$ 2,600,000
Period of written notice to terminate	90 days
Licensing Agreement | Scripps Research Institute | Research and Development
License and Collaboration Agreements
One-time cash payment				$ 10,000
Licensing Agreement | Vernalis (R&D) Limited
License and Collaboration Agreements
Milestone payments made	$ 0		$ 3,000,000
Period of written notice to terminate	90 days
Licensing Agreement | Vernalis (R&D) Limited | Maximum
License and Collaboration Agreements
Aggregate potential milestone payments	$ 220,000,000
Licensing Agreement | Vernalis (R&D) Limited | Research and Development
License and Collaboration Agreements
One-time cash payment					$ 1,000,000
Licensing Agreement | Monash License
License and Collaboration Agreements
Minimum annual fee		$ 25,000
Milestone payments made	0
Licensing Agreement | Monash License | Maximum
License and Collaboration Agreements
Aggregate potential milestone payments	$ 45,100,000
Licensing Agreement | Monash License | Research and Development
License and Collaboration Agreements
One-time cash payment		$ 275,000

Balance Sheet Components - Prep

Balance Sheet Components - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Prepaid and Other Current Assets
Interest receivable	$ 87	$ 37
Prepaid research and development manufacturing expenses	146	149
Prepaid facility expenses	196	196
Prepaid insurance	308	179
Other	240	220
Total of prepaid and other current assets	$ 977	$ 781

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property and Equipment
Property and equipment, gross	$ 4,792	$ 4,933
Less: accumulated depreciation and amortization	(4,600)	(4,697)
Property and equipment, net	192	236
Laboratory Equipment
Property and Equipment
Property and equipment, gross	2,537	2,678
Computer equipment and purchased software
Property and Equipment
Property and equipment, gross	171	171
Leasehold Improvements
Property and Equipment
Property and equipment, gross	$ 2,084	$ 2,084

Balance Sheet Components - Accr

Balance Sheet Components - Accrued and Other Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Accrued and Other Liabilities
Accrued clinical trial expense	$ 2,591,000		$ 2,591,000		$ 2,302,000
Accrued manufacturing expense	478,000		478,000		675,000
Personnel related	683,000		683,000		684,000
Accrued legal and accounting	322,000		322,000		64,000
Other	230,000		230,000		245,000
Total of accrued and other liabilities	4,304,000		4,304,000		$ 3,970,000
Depreciation expense	$ 21,000	$ 36,000	$ 44,000	$ 93,000

Warrants (Details)

Warrants (Details) - USD ($)		3 Months Ended	6 Months Ended
	May 06, 2024	Jun. 30, 2024	Jun. 30, 2024
Class of Warrant or Right [Line Items]
Warrants issued to purchase common shares		8,934,000	8,934,000
Adjustment to Additional Paid-in Capital upon issuance of warrants	$ 5,000,000	$ 5,031,000
Change in fair value of warrant liability		1,800,000	$ 1,816,000
Warrant liability	$ 8,900,000	$ 7,118,000	7,118,000
Common Stock
Class of Warrant or Right [Line Items]
Common shares issued in transaction		13,512,699
Registered Direct Offering | Common Stock
Class of Warrant or Right [Line Items]
Common shares issued in transaction	13,512,699
Registered Direct Offering | Warrants
Class of Warrant or Right [Line Items]
Warrants issued to purchase common shares	13,078,509
Offering price per share	$ 1.7312
Common Warrants | Warrants
Class of Warrant or Right [Line Items]
Warrants exercised		$ 0	$ 0
Common Warrants | Registered Direct Offering | Common Stock
Class of Warrant or Right [Line Items]
Exercise price of warrants	$ 3.50
Common Warrants | Registered Direct Offering | Warrants
Class of Warrant or Right [Line Items]
Warrants issued to purchase common shares	4,010,927
Offering price per share	$ 1.7311
Exercise price of warrants	$ 3.50
Pre-Funded Warrants | Warrants
Class of Warrant or Right [Line Items]
Warrants issued to purchase common shares		4,144,085	4,144,085
Warrants exercised		$ 0	$ 0
Pre-Funded Warrants | Registered Direct Offering | Warrants
Class of Warrant or Right [Line Items]
Warrants issued to purchase common shares	4,144,085
Offering price per share	$ 1.7311
Exercise price of warrants	0.0001
Exercise price of pre-funded warrants in lieu of common share warrants	$ 3.4999

Common Stock (Details)

Common Stock (Details)			6 Months Ended
	May 01, 2024 USD ($)	Mar. 28, 2023 USD ($)	Jun. 30, 2024 USD ($) Vote shares	Dec. 31, 2023 shares	Jun. 30, 2023 shares
Common Stock
Common stock, shares authorized for issuance			290,000,000		290,000,000
Preferred stock, shares authorized for issuance			10,000,000		10,000,000
Number of votes per share of common stock | Vote			1
Dividends on common stock | $			$ 0
Proceeds from sale of stock | $			$ 16,405,000
Shares of common stock reserved for issuance, on an as-converted basis
Pre-funded warrants			4,144,085
Outstanding common warrants			17,089,436
Shares available for future option grants			5,132,693	3,617,943
Outstanding options			9,690,400	9,244,150
Shares reserved for employee stock purchase plan			400,000	400,000
Total			36,456,614	13,262,093
At-the-market offering | Jefferies LLC | 2023 Sales Agreement
Common Stock
Stock issuance costs, as a percent of gross proceeds		3%
Common shares available for future sale | $			$ 100,000
At-the-market offering | Jefferies LLC | 2023 Sales Agreement | Maximum
Common Stock
Potential gross proceeds | $	$ 8,200,000	$ 90,000,000

Stock Option Plans - Stock Opti

Stock Option Plans - Stock Option Activity (Details) - $ / shares	1 Months Ended		6 Months Ended
	Mar. 31, 2016	Feb. 28, 2014	Jun. 30, 2024
Stock Option Plans
Shares available for future option grants			5,132,693
Shares Available for Grant
Shares Available for Grant, Opening Balance			3,617,943
Shares Available for Grant, Ending Balance			5,132,693
Number of Options
Outstanding Options, Opening Balance			9,244,150
Outstanding Options, Ending Balance			9,690,400
2014 Plan
Stock Option Plans
Vesting period		4 years
Maximum exercise term		10 years
Exercise price of common stock of its fair value (as a percent)		100%
Shares available for future option grants	0
Maximum number of options that may be re-issued under the 2016 plan	1,136,229
Shares Available for Grant
Shares Available for Grant, Ending Balance	0
2016 Plan
Stock Option Plans
Vesting period	4 years
Maximum exercise term	10 years
Exercise price of common stock of its fair value (as a percent)	100%
Shares available for future option grants			5,132,693
Shares Available for Grant
Shares Available for Grant, Opening Balance			3,617,943
Shares Available for Grant, Additional Shares Authorized			1,961,000
Shares Available for Grant, Options Granted			(525,000)
Shares Available for Grant, Options Forfeited			78,750
Shares Available for Grant, Ending Balance			5,132,693
Number of Options
Outstanding Options, Opening Balance			9,244,150
Outstanding Options, Granted			525,000
Outstanding Options, Forfeited			(78,750)
Outstanding Options, Ending Balance			9,690,400
Weighted-Average Exercise Price
Outstanding Options - Weighted Average Exercise Price, Opening Balance			$ 4.17
Outstanding Options - Weighted Average Exercise Price, Granted			2.26
Outstanding Options - Weighted Average Exercise Price, Forfeited			1.84
Outstanding Options - Weighted Average Exercise Price, Ending Balance			$ 4.08

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense Allocation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Stock-based compensation
Stock-based compensation expense	$ 768	$ 537	$ 1,457	$ 1,029
Research and Development
Stock-based compensation
Stock-based compensation expense	229	184	449	376
General and Administrative
Stock-based compensation
Stock-based compensation expense	$ 539	$ 353	$ 1,008	$ 653

Income Taxes - Components of Ea

Income Taxes - Components of Earnings Before Income Tax and Income Tax Benefits (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]
Net income (loss) before income tax	$ (3,685)	$ (5,219)	$ (9,622)	$ (11,361)
Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]
Income tax benefits			$ 0	$ 0

Facility Lease - Lessee informa

Facility Lease - Lessee information (Details) $ in Thousands	6 Months Ended		46 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Oct. 31, 2018 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2021 ft²	Feb. 01, 2015 ft²
Lease
Increase in operating lease right-of-use asset	$ 571	$ 526
Increase in the operating lease liability	674	602
Operating lease right-of-use asset	$ 578			$ 1,149
Sublease income - related party		$ 56
Laboratory Office Space
Lease
Area of leased facility | ft²					27,280	8,138
Lease term						1 year
Landlord Provided Free Rent And Lease Incentives			$ 1,900

Facility Lease - Lease cost (De

Facility Lease - Lease cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating lease cost
Total operating lease cost	$ 421	$ 391	$ 857	$ 808
Other Information
Operating cash flows used for operating lease	$ 473	$ 460	$ 946	$ 919
Remaining lease term	7 months 6 days	1 year 7 months 6 days	7 months 6 days	1 year 7 months 6 days
Discount rate	8%	8%	8%	8%
Research and Development
Operating lease cost
Operating lease costs	$ 306	$ 306	$ 615	$ 612
Costs of non-lease components (previously common area maintenance)	$ 115	$ 85	$ 242	$ 196

Facility Lease - Minimum rental

Facility Lease - Minimum rental commitments (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Minimum rental commitments 2023
2024*	$ 717
2024		$ 1,434
Total lease payments	717	1,434
Less: imputed interest	(17)	(60)
Total	$ 700	$ 1,374

Commitments and Contingencies -

Commitments and Contingencies - Line of Credit (Details) $ in Millions	Aug. 31, 2015 USD ($)
Line of credit
Security deposit	$ 0.1
Secured Debt
Line of credit
Line of credit	$ 0.1

Related Party Transactions (Det

Related Party Transactions (Details)		1 Months Ended	3 Months Ended	6 Months Ended
	May 06, 2024 USD ($) $ / shares shares	Aug. 31, 2021 ft²	Jun. 30, 2024 USD ($) shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Related Party Transactions
Sublease income - related party | $					$ 56,000
Public Offerings
Proceeds from sale of stock | $				$ 16,405,000
Warrants issued to purchase common shares			8,934,000	8,934,000
Angel Pharmaceuticals | Laboratory Office Space | Burlingame, California
Related Party Transactions
Area Of Property Subleased | ft²		7,585
Sublease income - related party | $					100,000
ICON plc
Related Party Transactions
Clinical Trial Expense | $				$ 155,000	$ 184,000
Common Stock
Public Offerings
Common shares issued in transaction			13,512,699
Pre-Funded Warrants | Warrants
Public Offerings
Warrants issued to purchase common shares			4,144,085	4,144,085
Registered Direct Offering
Public Offerings
Proceeds from sale of stock | $	$ 30,600,000
Registered Direct Offering | Peter Thompson, M.D., Orbimed Advisors, LLC
Public Offerings
Aggregate Purchase Price | $	2,499,856
Registered Direct Offering | Ted Wang, Ph.D., Pruissance Capital Management
Public Offerings
Aggregate Purchase Price | $	1,500,000
Registered Direct Offering | Richard A. Miller, M.D., CEO
Public Offerings
Aggregate Purchase Price | $	1,000,000
Registered Direct Offering | William B. Jones, Ph.D., Senior Vice President
Public Offerings
Aggregate Purchase Price | $	$ 34,624
Registered Direct Offering | Common Stock
Public Offerings
Common shares issued in transaction	13,512,699
Registered Direct Offering | Common Stock | Ted Wang, Ph.D., Pruissance Capital Management
Public Offerings
Common shares issued in transaction	866,451
Registered Direct Offering | Common Stock | Richard A. Miller, M.D., CEO
Public Offerings
Common shares issued in transaction	577,634
Registered Direct Offering | Common Stock | William B. Jones, Ph.D., Senior Vice President
Public Offerings
Common shares issued in transaction	20,001
Registered Direct Offering | Warrants
Public Offerings
Share offering price | $ / shares	$ 1.7312
Warrants issued to purchase common shares	13,078,509
Registered Direct Offering | Common Warrants | Common Stock
Public Offerings
Exercise price of warrants | $ / shares	$ 3.50
Registered Direct Offering | Common Warrants | Warrants
Public Offerings
Share offering price | $ / shares	$ 1.7311
Warrants issued to purchase common shares	4,010,927
Exercise price of warrants | $ / shares	$ 3.50
Registered Direct Offering | Common Warrants | Warrants | Peter Thompson, M.D., Orbimed Advisors, LLC
Public Offerings
Warrants issued to purchase common shares	1,397,684
Registered Direct Offering | Common Warrants | Warrants | Ted Wang, Ph.D., Pruissance Capital Management
Public Offerings
Warrants issued to purchase common shares	838,610
Registered Direct Offering | Common Warrants | Warrants | Richard A. Miller, M.D., CEO
Public Offerings
Warrants issued to purchase common shares	559,073
Registered Direct Offering | Common Warrants | Warrants | William B. Jones, Ph.D., Senior Vice President
Public Offerings
Warrants issued to purchase common shares	19,358
Registered Direct Offering | Pre-Funded Warrants | Warrants
Public Offerings
Share offering price | $ / shares	$ 1.7311
Warrants issued to purchase common shares	4,144,085
Exercise price of pre-funded warrants in lieu of common share warrants | $ / shares	$ 3.4999
Exercise price of warrants | $ / shares	$ 0.0001
Registered Direct Offering | Pre-Funded Warrants | Warrants | Peter Thompson, M.D., Orbimed Advisors, LLC
Public Offerings
Warrants issued to purchase common shares	1,444,085
Angel Pharmaceuticals
Related Party Transactions
Ownership interest (as percent)			49.70%	49.70%	49.70%
Angel Pharmaceuticals | Ted Wang, Ph.D., Pruissance Capital Management
Related Party Transactions
Ownership interest (as percent)			49.70%	49.70%
Angel Pharmaceuticals | Angel Pharmaceuticals
Related Party Transactions
Ownership interest (as percent)			49.70%	49.70%
Third-party costs | $				$ 9,000	$ 48,000
Accounts receivable | $			$ 35,000	35,000		$ 26,000
Related party research service costs | $				$ 0	$ 200,000